June 27, 2017
Sumitomo Dainippon Pharma suffered a setback in a PIII study investigating its hoped-to-be blockbuster napabucasin for the treatment of gastric and gastroesophageal junction cancer, as an independent data monitoring committee found that the drug is unlikely to extend overall survival...read more